Skip to main content

Table 1 Current active trials in HNSCC with novel single agentsa

From: Genomically personalized therapy in head and neck cancer

Trial Number

Trial phase

Drug

Pathway targeted

Molecular selection

Setting

Status

NCT02429089

1

LEE011

Cell cycle

No

Recurrent, metastatic

Recruiting

NCT02264678

1, 2

AZD6738

DNA repair

No

Recurrent, metastatic, in combination with chemotherapy or MEDI4736 or olaparib

Recruiting

NCT02567396

1

Talazoparib

DNA repair

No

Recurrent, metastatic

Not yet recruiting

NCT01711541

1, 2

Veliparib

DNA repair

No

Recurrent, metastatic, in combination with chemotherapy

 

NCT02365662

1

ABBV-221

EGFR

No

Recurrent, metastatic

Recruiting

NCT01345669

3

Afatinib

ERBB

No

Placebo controlled post-chemoradiotherapy

Recruiting

NCT01415674

2

Afatinib

ERBB

No

Neoadjuvant

Active, not recruiting

NCT01427478

3

Afatinib

ERBB

No

Placebo controlled randomised phase 3, maintenance therapy after post-operative chemoradiotherapy

Recruiting

NCT02131155

3

Afatinib

ERBB

No

Placebo controlled adjuvant trial

Recruiting

NCT02216916

2

HM781-36B

ERBB

No

Recurrent, metastatic

Recruiting

NCT02145312

2

BYL719

PI3K

No

Recurrent, metaststic

Not yet recruiting

NCT02540928

2a

AMG319

PI3K

HPV-negative

Placebo controlled neoadjuvant therapy

Recruiting

  1. aClinical trials with immune checkpoint inhibitors are not included in this Table